Learning Objectives:
Describe Recent Progress In The Diagnosis And Management Of aTTR Amyloidosis


Frederick L. Ruberg, MD., Presenter, received a Grant/Research Support-educational training fellowship from Pfizer, Grant/Research Support from kcea/Ionis Pharmaceuticals & Alnylam Pharmaceuticals oncardiac amyloidosis research, and a consultant for Atrtralus on clinical trial advising.

Faculty does  plan to discuss the uses of an investigational product: diflunisal for ATTR amyloidosis treatment, Tc-99m PYP for ATTR amyloidosis diagnosis, clinical trials involving patisiran, vutrisiran, eplontersen, and acoramidis

Session date: 
03/15/2023 - 12:00pm to 1:00pm EDT
Location: 
Boston Medical Center
72 E. Concord ST
Collamore-8
Boston, MA 02118
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
Please login or register to take this course.